Follicular Lymphoma Current Management and Novel Approaches
This book provides a comprehensive, state-of-the-art overview of follicular lymphoma. The first section of the text explores the current understanding of the biology and pathogenesis of follicular lymphoma, through reviewing recent changes in the WHO clas
- PDF / 8,240,668 Bytes
- 237 Pages / 439.43 x 683.15 pts Page_size
- 64 Downloads / 230 Views
123
Follicular Lymphoma
Nathan H. Fowler Editor
Follicular Lymphoma Current Management and Novel Approaches
Editor Nathan H. Fowler Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Houston, TX USA
ISBN 978-3-030-26210-5 ISBN 978-3-030-26211-2 (eBook) https://doi.org/10.1007/978-3-030-26211-2 © Springer Nature Switzerland AG 2020 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
Few things strike fear into the clinician and patient as the word “cancer.” Despite decades of research and countless dollars, the majority of cancers remain incurable, and therapy carries a high cost, both financially and on patients’ short- and long- term quality of life. With the exception of very early-stage malignancies, most cancers carry a high risk of relapse following frontline treatment. Side effects occur often, can be severe, and are unpredictable. Fortunately, due to technical advances, emerging science, and a fundamental shift in new drug development, we are witnessing dramatic improvements in life expectancy and treatment tolerability across a spectrum of malignancies. For years, follicular lymphoma has remained a disease with more questions than answers. The natural history can be highly variable, and clinical information at diagnosis only occasionally predicts a patient’s long-term outcome. Some patients achieve spontaneous remission in the absence of therapy, while others transform or fail high-dose chemotherapy in short order. Historically, attempts to biologically define these dramatically different patient groups have been largely unsuccessful. Although the cell of origin and the hallmark mutation have been well described, very few targeted ther
Data Loading...
